Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Prioritizes Vinpocetine Decison After Animal Study Shows 'Developmental Toxicity'

Jun 04 2019

• By Malcolm Spicer

LabmicroscopeDNAgel_1200x675

Related Content

XXL Impressions Supplement Memory Claims Impress FTC As False

Feb 23 2017

FDA Opens Extra-Regulatory Enforcement Door On Vinpocetine – CRN, NPA

Nov 08 2016

FDA Guidance Makes Vinpocetine Compliant Despite Ban Proposal – NPA

Dec 01 2016

'Innovation' Meeting Shows FDA-Industry Gap On NDI Guidance Details Remains

May 20 2019

FDA Debuts List For Rapidly Announcing Noncompliant Ingredients In Supplements

Apr 17 2019

Additional Topics

United States Dietary Supplements FDA Enforcement Commercial Compliance Ingredients Manufacturing Regulation Safety Consumer

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.